News >

Therapeutic Advancements Changing Liver Cancer Paradigm

Danielle Bucco
Published: Monday, Sep 25, 2017

Steven R. Alberts, MD

Steven R. Alberts, MD
For nearly a decade after the 2007 approval of sorafenib (Nexavar), there were no new therapies approved for HCC. However, there are now new drugs showing promise, according to Steven R. Alberts, MD.

on GI Malignancies, Alberts, a professor of oncology in the College of Medicine, consultant in the Division of Medical Oncology at Mayo Clinic, discussed current advancements being made for patients with advanced liver cancer.

OncLive: Please provide an overview of your presentation.

Alberts: I went over some updates regarding the treatment of patients with advanced liver cancer. I spent some time reviewing the management of smaller, localized tumors that may be treated with embolization. However, the bulk of the talk was focused on systemic therapy for advanced disease. 

What regimens are looking promising for advanced liver cancer?

It is an interesting time in liver cancer. For many years, it was sorafenib and not much else. There were a lot of trials that had been conducted in early phases that showed promising results, but none of those made it to FDA approval until regorafenib. Since then, there have been several drugs heading toward hopefully successful trials.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x